|
Reference 1. Ostrom, Q.T., et al., The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol, 2014. 16(7): p. 896-913. 2. Ostrom, Q.T., et al., CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol, 2014. 16 Suppl 4: p. iv1-63. 3. Louis, D.N., et al., The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 2007. 114(2): p. 97-109. 4. Malmström, A., et al., Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The Lancet Oncology, 2012. 13(9): p. 916-926. 5. Wong, E.T., et al., Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol, 1999. 17(8): p. 2572-8. 6. Ballman, K.V., et al., The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol, 2007. 9(1): p. 29-38. 7. Brandenburg, S., et al., Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathol, 2016. 131(3): p. 365-78. 8. Chae, M., et al., Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro Oncol, 2015. 17(7): p. 978-91. 9. Wang, S.C., et al., Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab Invest, 2012. 92(1): p. 151-62. 10. Gordon, S. and F.O. Martinez, Alternative Activation of Macrophages: Mechanism and Functions. Immunity, 2010. 32(5): p. 593-604. 11. Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of macrophage subsets. Nature reviews. Immunology, 2011. 11(11): p. 723-737. 12. De Palma, M. and Claire E. Lewis, Macrophage Regulation of Tumor Responses to Anticancer Therapies. Cancer Cell. 23(3): p. 277-286. 13. Mantovani, A., et al., Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol, 2013. 229(2): p. 176-85. 14. Mantovani, A., et al., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 2002. 23(11): p. 549-555. 15. Zhou, M., et al., Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time. Int J Cancer, 2015. 137(4): p. 826-36. 16. Bingle, L., et al., Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br J Cancer, 2006. 94(1): p. 101-7. 17. De Palma, M., et al., Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 2005. 8(3): p. 211-226. 18. Squadrito, Mario L., et al., miR-511-3p Modulates Genetic Programs of Tumor-Associated Macrophages. Cell Reports, 2012. 1(2): p. 141-154. 19. Yuan, A., et al., Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression. Scientific Reports, 2015. 5: p. 14273. 20. Lanciotti, M., et al., The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res Int, 2014. 2014: p. 486798. 21. Laoui, D., et al., Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol, 2011. 55(7-9): p. 861-7. 22. Liu, C.Y., et al., M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest, 2013. 93(7): p. 844-54. 23. Rossi, M.L., et al., Immunocytochemical study of the cellular immune response in meningiomas. Journal of Clinical Pathology, 1988. 41(3): p. 314-319. 24. Morantz, R.A., et al., Macrophages in experimental and human brain tumors. Journal of Neurosurgery, 1979. 50(3): p. 305-311. 25. Simmons, G.W., et al., Neurofibromatosis-1 Heterozygosity Increases Microglia in a Spatially- and Temporally-Restricted Pattern Relevant to Mouse Optic Glioma Formation and Growth. Journal of neuropathology and experimental neurology, 2011. 70(1): p. 51-62. 26. Gutmann, D.H., et al., Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Research, 2013. 23(3): p. 431-439. 27. Hambardzumyan, D., D.H. Gutmann, and H. Kettenmann, The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci, 2016. 19(1): p. 20-7. 28. Saito, M., et al., Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat Biotechnol, 2001. 19(8): p. 746-50. 29. Van Ness, B.G., J.B. Howard, and J.W. Bodley, ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. Journal of Biological Chemistry, 1980. 255(22): p. 10710-10716. 30. Robinson, E.A., O. Henriksen, and E.S. Maxwell, Elongation Factor 2: AMINO ACID SEQUENCE AT THE SITE OF ADENOSINE DIPHOSPHATE RIBOSYLATION. Journal of Biological Chemistry, 1974. 249(16): p. 5088-5093. 31. Honjo, T., et al., Diphtheria Toxin-dependent Adenosine Diphosphate Ribosylation of Aminoacyl Transferase II and Inhibition of Protein Synthesis. Journal of Biological Chemistry, 1968. 243(12): p. 3553-3555. 32. Stoneman, V., et al., Monocyte/Macrophage Suppression in CD11b Diphtheria Toxin Receptor Transgenic Mice Differentially Affects Atherogenesis and Established Plaques. Circulation research, 2007. 100(6): p. 884-893. 33. Fillat, C., et al., Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application. Current Gene Therapy, 2003. 3(1): p. 13-26. 34. Moolten, F.L., Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy. Cancer Research, 1986. 46(10): p. 5276-5281. 35. Duarte, S., et al., Suicide gene therapy in cancer: Where do we stand now? Cancer Letters, 2012. 324(2): p. 160-170. 36. Takamiya, Y., et al., Gene therapy of maliganant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. Journal of Neuroscience Research, 1992. 33(3): p. 493-503. 37. Freeman, S.M., et al., The “Bystander Effect”: Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified. Cancer Research, 1993. 53(21): p. 5274-5283. 38. Moolten, F.L. and J.M. Wells, Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transfered by Retroviral Vectors. Journal of the National Cancer Institute, 1990. 82(4): p. 297-300. 39. Caruso, M., et al., Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proceedings of the National Academy of Sciences of the United States of America, 1993. 90(15): p. 7024-7028. 40. Mesnil, M. and H. Yamasaki, Bystander Effect in Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Cancer Gene Therapy: Role of Gap-junctional Intercellular Communication1. Cancer Research, 2000. 60(15): p. 3989-3999. 41. van Dillen, I.J., et al., Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review. Current Gene Therapy, 2002. 2(3): p. 307-322. 42. Chiang, C.S., et al., Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol, 2012. 2: p. 89. 43. Marilena Campanella, C.S., Glauco Tarozzo, and Massimiliano Beltramo, Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke. 2002;33:586-592, doi:10.1161/hs0202.103399, 2002. 44. Romero, I.L., et al., Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res, 2015. 21(4): p. 680-6. 45. Frieler, R.A., et al., Depletion of macrophages in CD11b diphtheria toxin receptor mice induces brain inflammation and enhances inflammatory signaling during traumatic brain injury. Brain Res, 2015. 1624: p. 103-12. 46. Duffield, J.S., et al., Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. The Journal of Clinical Investigation. 115(1): p. 56-65. 47. . 48. Leek, R.D., et al., Association of Macrophage Infiltration with Angiogenesis and Prognosis in Invasive Breast Carcinoma. Cancer Research, 1996. 56(20): p. 4625-4629. 49. Lamagna, C., M. Aurrand-Lions, and B.A. Imhof, Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol, 2006. 80(4): p. 705-13. 50. OHNO, S., et al., Correlation of Histological Localization of Tumor-associated Macrophages with Clinicopathological Features in Endometrial Cancer. Anticancer Research, 2004. 24(5C): p. 3335-3342. 51. Coffelt, S.B., R. Hughes, and C.E. Lewis, Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta, 2009. 1796(1): p. 11-8. 52. Redente, E.F., et al., Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol, 2010. 176(6): p. 2972-85. 53. Lin, E.Y., et al., Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer. Cancer Research, 2006. 66(23): p. 11238-11246. 54. Hochweller, K., et al., A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol, 2008. 38(10): p. 2776-83. 55. Jung, S., et al., In Vivo Depletion of CD11c+ Dendritic Cells Abrogates Priming of CD8+ T Cells by Exogenous Cell-Associated Antigens. Immunity, 2002. 17(2): p. 211-220. 56. Ma, Y., et al., Autophagy and Cellular Immune Responses. Immunity. 39(2): p. 211-227. 57. Dijkgraaf, E.M., et al., Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment. Cancer Research, 2013. 73(8): p. 2480-2492. 58. DeNardo, D.G., et al., Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011. 1(1): p. 54-67. 59. Shree, T., et al., Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes & Development, 2011. 25(23): p. 2465-2479. 60. Paulus, P., et al., Colony-Stimulating Factor-1 Antibody Reverses Chemoresistance in Human MCF-7 Breast Cancer Xenografts. Cancer Research, 2006. 66(8): p. 4349-4356. 61. Mantovani, A. and P. Allavena, The interaction of anticancer therapies with tumor-associated macrophages. The Journal of Experimental Medicine, 2015. 212(4): p. 435-445. 62. Hanahan, D. and Robert A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell, 2011. 144(5): p. 646-674. 63. Coffelt, S.B., et al., Elusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in Tumors. The American Journal of Pathology, 2010. 176(4): p. 1564-1576. 64. Piao, Y., et al., Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncology, 2012. 14(11): p. 1379-1392. 65. Lu-Emerson, C., et al., Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology, 2013. 15(8): p. 1079-1087. 66. Kolaczkowska, E. and P. Kubes, Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol, 2013. 13(3): p. 159-175. 67. Nauseef, W.M. and N. Borregaard, Neutrophils at work. Nat Immunol, 2014. 15(7): p. 602-611. 68. Kruger, P., et al., Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury. PLoS Pathogens, 2015. 11(3): p. e1004651. 69. Dvorak , H.F., Tumors: Wounds That Do Not Heal. New England Journal of Medicine, 1986. 315(26): p. 1650-1659. 70. Lakshman, R. and A. Finn, Neutrophil disorders and their management. Journal of Clinical Pathology, 2001. 54(1): p. 7-19. 71. Bekes, E.M., et al., Tumor-Recruited Neutrophils and Neutrophil TIMP-Free MMP-9 Regulate Coordinately the Levels of Tumor Angiogenesis and Efficiency of Malignant Cell Intravasation. The American Journal of Pathology, 2011. 179(3): p. 1455-1470. 72. Powell, D.R. and A. Huttenlocher, Neutrophils in the Tumor Microenvironment. Trends in Immunology, 2016. 37(1): p. 41-52. 73. Nozawa, H., C. Chiu, and D. Hanahan, Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006. 103(33): p. 12493-12498. 74. Rao, H.-L., et al., Increased Intratumoral Neutrophil in Colorectal Carcinomas Correlates Closely with Malignant Phenotype and Predicts Patients' Adverse Prognosis. PLoS ONE, 2012. 7(1): p. e30806. 75. Li, Y.-W., et al., Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. Journal of Hepatology, 2011. 54(3): p. 497-505. 76. Jensen, T.O., et al., Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer, 2012. 118(9): p. 2476-2485. 77. Jensen, H.K., et al., Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma. Journal of Clinical Oncology, 2009. 27(28): p. 4709-4717. 78. Trellakis, S., et al., Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. International Journal of Cancer, 2011. 129(9): p. 2183-2193. 79. Prinz, M. and J. Priller, Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci, 2014. 15(5): p. 300-312. 80. Frieler, R.A., et al., Depletion of macrophages in CD11b diphtheria toxin receptor mice induces brain inflammation and enhances inflammatory signaling during traumatic brain injury. Brain Research, 2015. 1624: p. 103-112. 81. Ueno, M., et al., Layer V cortical neurons require microglial support for survival during postnatal development. Nat Neurosci, 2013. 16(5): p. 543-551. 82. Ding, Z., et al., Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. The Journal of Experimental Medicine, 2014. 211(2): p. 189-198. 83. Zhao, L., et al., Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology, 2013. 57(2): p. 829-39. 84. Probst, H.C., et al., Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Clinical and Experimental Immunology, 2005. 141(3): p. 398-404. 85. Hochweller, K., et al., A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. European Journal of Immunology, 2008. 38(10): p. 2776-2783. 86. Männ, L., et al., CD11c.DTR mice develop a fatal fulminant myocarditis after local or systemic treatment with diphtheria toxin. European Journal of Immunology, 2016. 87. Munn, D.H., et al., Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism. The Journal of Experimental Medicine, 1999. 189(9): p. 1363-1372. 88. Rodriguez, P.C., et al., l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes. The Journal of Immunology, 2003. 171(3): p. 1232-1239. 89. Sharda, D.R., et al., Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase. Journal of immunology (Baltimore, Md. : 1950), 2011. 187(5): p. 2181-2192. 90. Kuang, D.-M., et al., Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. The Journal of Experimental Medicine, 2009. 206(6): p. 1327-1337. 91. Zhu, Y., et al., CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T Cell Checkpoint Immunotherapy in Pancreatic Cancer Models. Cancer research, 2014. 74(18): p. 5057-5069. 92. Pyonteck, S.M., et al., CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature medicine, 2013. 19(10): p. 1264-1272. 93. Ries, Carola H., et al., Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 2014. 25(6): p. 846-859.
|